Moreover, the survival data of patients with HL treated with ICI combination therapies and CD30/CD16A BSABs revealed that ICI combination therapies might facilitate longer PFS (Fig. 2b and Supplementary Table S1). This evidence concerns the gene FCGR3A and Hodgkins lymphoma.